Visual Performance of Four Types of Multifocal Intraocular Lenses

NCT ID: NCT03454334

Last Updated: 2022-04-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

141 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-08-11

Study Completion Date

2020-01-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This investigation assessed the visual performance of presbyopia and cataract patients after bilateral implantation of 4 distinct sorts of multifocal IOLs: At lisa tri, PanOptix, ReSTOR, and Symfony. The clinical results demonstrated here were excellent for four groups, however, there were also differences in group ReSTOR, UCVA and BCVA for the intermediate and near of the other groups showed less vision also symphony group for far distance demonstrated less vision than other groups, which may be related to their design.Multifocal IOLs demonstrated very good technology and unquestionably have a place in refractive surgery, whether for clear lens extraction or cataracts.Patients can expect excellent outcomes and surgeons can expect patients to be very satisfied with surgical outcomes. Four groups multifocal lenses provided excellent distance, intermediate and near vision, but several measures indicated that the PanOptix and at lisa tri lens provided better vision in all distances. Spectacle independence was significantly higher with four groups. Multifocal IOL design might play a role in the postsurgical outcome, because better results were obtained with diffractive lenses. Although there were differences in the results of these four lenses in the study, all of the results were acceptable.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cataract

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

AMO Tecnis Symfony

Multifocal with extended range of vision, Diffractive, No Preloaded, Aspheric, +3.25 D near add and +2.17 D intermediate 6.0mm Hydrophilic

-0.20

Has nine diffractive steps, The proprietary achromatic technology corrects chromatic aberration. This creates improved contrast sensitivity.

Group Type ACTIVE_COMPARATOR

multifocal intraocular lens IOLs

Intervention Type DEVICE

clinical outcome of different multifocal intraocular lenses (IOLs) in patients with presbyopia or cataracts

AcrySof ReSTOR (Alcon Laboratories)

Multifocal ,Diffractive, +3.00D and for Near, Aspheric, Has 9 steps (rings), Light: 41% for far; 41% for near: 18% reflected (lost).

6.0mm Silicone

-0.10 Bifocal ,One piece,Blue filter ,Central diffractive region of 3.6\_mm for near and distance vision ,Apodised ,peripheral refractive region is dedicated to distance vision

Group Type ACTIVE_COMPARATOR

multifocal intraocular lens IOLs

Intervention Type DEVICE

clinical outcome of different multifocal intraocular lenses (IOLs) in patients with presbyopia or cataracts

AT Lisa tri (CarlZeiss Meditec AG)

Trifocal, diffractive, +3.33 D near add and +1.66 D intermediate add at the IOL plane, aspheric (aberration correcting) Optic Diameter 6.0 mm Total Diameter 11.0 mm Haptic Angulation 0° Lens Design Single-piece, MICS Incision Size 1.8 mm Company Labeled A-Constant1 118.6 Diopter Range 0.0 to +32.0 D, 0.5 D increments ACD 5.32

Group Type ACTIVE_COMPARATOR

multifocal intraocular lens IOLs

Intervention Type DEVICE

clinical outcome of different multifocal intraocular lenses (IOLs) in patients with presbyopia or cataracts

PanOptix(Alcon Laboratories)

Trifocal,Difractive,+3.25D Near,+2.17 D intermediate 6.0mm hydrophobic

-0.27 One piece ,aspheric , Focal 4.5 mm (15 diffractive zones)

Group Type ACTIVE_COMPARATOR

multifocal intraocular lens IOLs

Intervention Type DEVICE

clinical outcome of different multifocal intraocular lenses (IOLs) in patients with presbyopia or cataracts

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

multifocal intraocular lens IOLs

clinical outcome of different multifocal intraocular lenses (IOLs) in patients with presbyopia or cataracts

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Preoperative BCVA (distance) more impacted than 20/40
* Glare VA test comes about worse than 20/40, or practically impairing dissensions about their vision.
* By reviewing and judging the researchers, individuals also had a potential need for visual acuity of 20/30 or better after surgery.
* Express a want for multifocal vision, and be ready and ready to conform to the investigation necessities

Exclusion Criteria

* Excluded from entry were subjects with regular astigmatism greater than 1.5 D or irregular astigmatism.
* Large pupil
* Corneal transplant surgery or previous glaucoma-filtering,
* A history of retinal detachments.
* Also excluded were patients with other clinically non-cataract ocular abnormality (e.g. chronic drug-induced miosis,
* Endothelial disease
* Iris neovascularization, and amblyopia)
Minimum Eligible Age

40 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Shahid Beheshti University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

farinaz doroodgar

Ophthalmologist

Responsibility Role PRINCIPAL_INVESTIGATOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ShahedBU

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.